Why Doesn't High-Dose Chemotherapy Improve Survival, as Was Expected, in Advanced or Relapsed Germ Cell Tumours?

European Urology

Volumn 56, Issue 1, 2009, Pages 46-47

  Pizzocaro, Giorgio ^a   Guarneri, Andrea ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; VINBLASTINE;

ABDOMINAL MASS; ACCURACY; ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; GERM CELL TUMOR; HEARING LOSS; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETROPERITONEAL CANCER; TESTIS CANCER; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TESTICULAR NEOPLASMS;

EID: 67349189170     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.019     Document Type: Editorial

References (10)

1. Gottesman M.M. Mechanism of cancer drug resistance. Ann Rev Med 53 (2002) 615-627
2. Connolly R., and McCaffrey J. High-dose chemotherapy and stem cell transplant in advanced germ cell cancer: a review. Eur Urol 56 (2009) 57-64
3. Samson M.K., Riwkin S.E., Jones S.E., et al. Dose response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group Study. Cancer 53 (1984) 1029-1035
4. Ozols R.F., Ihde D.C., and Linehan W.M. A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6 (1988) 1031-1040
5. Pizzocaro G., Piva L., Salvioni R., Zanoni F., and Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer 56 (1985) 2411-2415
6. Nichols C.R., Williams S.P., Loehrer P.J., et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumours: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9 (1991) 1163-1172
7. Cushing B., Giller R., and Cullen J.W. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22 (2004) 2691-2700
8. Einhorn L.H. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99 (2002) 4592-4595
9. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14 (2009) 3-9
10. Nicolai N, Necchi A, Gianni L, et al. Long term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumour. BJU Int. In press. doi:10.1111/j.1464-410x2009.